The revised target comes in response to ICON's 2025 ... For detailed insights into ICON's financial health and growth prospects, investors can access the full Pro Research Report, available ...

BofA analyst Michael Ryskin lowered the firm’s price target on Icon (ICLR) to $255 from $270 and keeps a Buy rating on the shares. The firm ...

TD Cowen adjusted its financial outlook for ICON plc (NASDAQ:ICLR), a global provider of drug development solutions and services to the pharmaceutical, biotechnology, and medical device industries.

ICON plc, (NASDAQ: ICLR), a world-leading clinical research organization powered by healthcare intelligence, today announced its financial guidance for the year ending December 31, 2025.